David Einhorn Has 7 New Stock Picks: Hedge Fund Manager Bets on Buyouts, Spinoffs
A hedge fund is betting on spinoffs and buyouts for several of its new portfolio holdings.
Read original at benzingaStocks · News reference
Dick's Sporting To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday
Analysts update ratings on top stocks. View all changes, including upgrades and downgrades, on analyst ratings page.
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 10, 2026, 12:23 PM
- Checked
- Aug 10, 2026, 12:23 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Evercore ISI Group Maintains Outperform on Aptiv, Lowers Price Target to $70
Evercore ISI Group analyst Chris McNally maintains Aptiv (NYSE:APTV) with a Outperform and lowers the price target from $80 to $70.
Read original at benzingaHigh Performance Fluoropolymers Market Forecast 2026-2032 | Semiconductor, Electric Vehicle and Battery Demand Accelerates High Performance Fluoropolymers Market Growth
The global high-performance fluoropolymers market is projected to grow from USD 5.17 billion in 2026 to USD 7.82 billion by 2032 at a CAGR of 7.11%, driven by semiconductor fabrication, electric vehicle electrification, battery technology, and hydrogen infrastructure demands. Key growth factors include regulatory compliance requirements, AI-driven innovation in materials discovery, and expanding applications across aerospace, medical devices, and industrial coatings.
Read original at globenewswire-incJP Morgan Maintains Neutral on Chemours, Lowers Price Target to $15
JP Morgan analyst Jeffrey Zekauskas maintains Chemours (NYSE:CC) with a Neutral and lowers the price target from $22 to $15.
Read original at benzingaBMO Capital Maintains Outperform on Chemours, Lowers Price Target to $18
BMO Capital analyst John McNulty maintains Chemours (NYSE:CC) with a Outperform and lowers the price target from $26 to $18.
Read original at benzingaChemours shares are trading lower after UBS downgraded the stock from Buy to Neutral and lowered its price target from $29 to $18.
Read original at benzinga